Evolus
About Evolus
Evolus Inc. is a privately held company focused on bringing highly innovative products and services to the aesthetics market.YEAR FOUNDED:
2012
LEADERSHIP:
CEO: Murthy Simhambhatla
COO: Chris Marmo
CMO: Rui Avelar
121 articles about Evolus
-
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 12, 2024
4/12/2024
Evolus, Inc., a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, reported the grant of non-qualified stock options to purchase an aggregate of 9,651 shares of Evolus and an aggregate of 20,971 restricted stock units of the company’s common stock to 10 newly hired non-executive employees of the company.
-
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
3/11/2024
Evolus, Inc. announced the pricing of its underwritten offering of 3,554,000 shares of its common stock at a underwritten offering price of $14.07 per share, which is equal to the closing price on Friday, March 8, 2024, before underwriting discounts and commissions.
-
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 08, 2024
3/8/2024
Evolus, Inc., a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, reported the grant of non-qualified stock options to purchase an aggregate of 11,355 shares of Evolus and an aggregate of 82,730 restricted stock units of the company’s common stock to 8 newly hired non-executive employees of the company.
-
Evolus Announces Results from European Head-to-Head Filler Trial
3/1/2024
Evolus, Inc. today announced that it will provide the data presented at IMCAS during its upcoming Earnings conference call on March 7th at 4:30 p.m. ET.
-
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
2/27/2024
Evolus, Inc. today announced that members of its management team will present at the following investor conferences in March.
-
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 09, 2024
2/9/2024
Evolus, Inc., a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, reported the grant of an aggregate of 15,101 restricted stock units of the company’s common stock to 7 newly hired non-executive employees of the company.
-
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
1/16/2024
Evolus, Inc., a global performance beauty company with a focus on building an aesthetic portfolio, announced its preliminary, unaudited net revenue for the fourth quarter and full-year ended December 31, 2023.
-
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 12, 2024
1/12/2024
Evolus, Inc. reported the grant of non-qualified stock options to purchase an aggregate of 89,770 shares of Evolus and an aggregate of 82,730 restricted stock units of the company’s common stock to six newly hired non-executive employees of the company.
-
Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications
1/4/2024
Evolus, Inc. announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications.
-
Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
12/20/2023
Evolus, Inc. announced it has entered into a definitive agreement with Symatese to be the exclusive distributor in the United Kingdom and Europe of four unique dermal fillers in late-stage development with anticipated regulatory clearances in second half of 2024 and commercialization under the brand name Estyme® fillers in 2025.
-
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 10, 2023
11/10/2023
Evolus, Inc. reported the grant in October of non-qualified stock options to purchase an aggregate of 63,703 shares of Evolus and an aggregate of 70,320 restricted stock units of the company’s common stock to 8 newly hired non-executive employees of the company.
-
Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®
11/7/2023
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the third quarter ended September 30, 2023.
-
“Extra-Strength” 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting
11/6/2023
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, announced results from the Phase 2 clinical study evaluating the “extra-strength” 40U dose for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs), the only neurotoxin dedicated exclusively to aesthetics.
-
Evolus to Participate in November Investor Conferences
11/1/2023
Evolus, Inc. today announced that members of its management team will present at the following investment conferences in November.
-
Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting
10/25/2023
Evolus, Inc. today announced that Sue Ellen Cox M.D. will present final results from the Phase 2 study evaluating the safety, efficacy and duration of effect of 40U PrabotulinumtoxinA-xvfs at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting on November 3, 2023, in Chicago during an independent medical education session.
-
Evolus to Report Third Quarter 2023 Results
10/25/2023
Evolus, Inc. today announced that it will report its third quarter 2023 financial results and provide a business update on Tuesday, November 7, 2023, after the U.S. financial markets close.
-
Evolus to Participate in September 2023 Conferences
8/29/2023
Evolus, Inc., a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, announced that members of its management team will be participating in two investment conferences in September.
-
Evolus Announces Inducement Grants for New Chief Marketing Officer
8/23/2023
Evolus, Inc. announced that the Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 83,555 shares of Evolus common stock and 63,358 restricted stock units to Tomoko Yamagishi-Dressler, the company’s new Chief Marketing Officer.
-
Evolus Reports Second Quarter 2023 Results and Provides Business Update
8/2/2023
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.
-
Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue
7/27/2023
Evolus, Inc., a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, reported revenue for the second quarter ended June 30, 2023 and raised its revenue guidance for the full year.